EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseOpen Access · CC BY-NC-ND 4.0

Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures

Chenning Liu, Liyang Lyu, Yufan Zhang, Yingyi Tian, Jing Yuan, Chihua Li, Yuanjia Hu

International Journal of Clinical Pharmacy · 17.03.2026 · 48 (4) · 1412-1423

DOI: 10.1007/s11096-026-02119-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 17.03.2026. Verfasst von Chenning Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Development Fund of Macau SAR, University of Macau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The introduction of Accelerated Drug Marketing Registration Procedures (ADMRPs) in China has improved patient access to innovative therapies, but concerns remain about the robustness and consistency of efficacy evidence. AIM: This study aimed to compare the treatment efficacy of approved targeted therapies for non-small cell lung cancer (NSCLC) before and after the implementation of ADMRPs. METHOD: In this retrospective study, we analyzed targeted therapies for NSCLC approved in China as of December 31, 2024. Approvals were categorized as pre-policy or post-policy groups based on the July 1, 2020 implementation of ADMRPs. Descriptive statistics were used to examine approved indications and pivotal trial designs. Meta-analysis and meta-regression compared pre-approval efficacy outcomes, including overall survival (OS), progression-free survival (PFS), disease-free survival, and objective response rate (ORR), between groups. Sensitivity analyses evaluated post-marketing OS data and the robustness of results. RESULTS: A total of 59 indications supported by 72 trials were approved. Post-policy approvals increased markedly (41 vs 18), with rises in domestic drugs (16.7% pre-policy vs 61.0% post-policy) and uncommon targets (5.6% pre-policy vs 43.9% post-policy) (both P < 0.05). Pivotal trials shifted from primarily Phase III-IV randomized controlled trials (RCTs) (76.0%) pre-policy to Phase I-II single-arm designs (68.1%) post-policy, mainly supporting drugs for uncommon or resistance mutations, whereas approvals for classical targets remained predominantly based on RCTs (90.0% pre-policy vs 93.8% post-policy; P = 0.416). Meta-analyses found no significant differences in pre-approval efficacy between groups for PFS (HR: 0.52 [0.45-0.61] vs 0.44 [0.36-0.54]; P = 0.206) or ORR (0.63 [0.55-0.70] vs 0.65 [0.59-0.70]; P = 0.705). However, OS meta-analysis was only feasible in the pre-policy group, whereas OS data in the post-policy group remained immature, with a median follow-up of 17 months (IQR 8-34) after approval. CONCLUSION: After the introduction of ADMRPs, approvals of targeted therapies for NSCLC increased substantially, without significant loss of pre-approval treatment efficacy. However, due to the limited follow-up, definitive survival benefits for the post-policy group cannot yet be established. The increased reliance on single-arm trials underscores the necessity of rigorous confirmatory post-marketing studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug ApprovalAntineoplastic AgentsMolecular Targeted TherapyHumansChinaTreatment OutcomeRetrospective StudiesProgression-Free Survival

Stichwörter der Autor:innen

Accelerated drug marketing registration proceduresChinaNon-small cell lung cancerOverall survival benefitTargeted therapyTreatment efficacy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
  • State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
  • Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
  • DPM, Faculty of Health Sciences, University of Macau, Macao SAR, China. chihuali@um.edu.mo.
  • State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. yuanjiahu@um.edu.mo.
  • Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao SAR, China. yuanjiahu@um.edu.mo.

Förderung

  • Science and Technology Development Fund of Macau SAR
  • University of Macau

Zitieren

APA

Liu, C., Lyu, L., Zhang, Y., Tian, Y., Yuan, J., Li, C., & Hu, Y. (2026). Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures. International Journal of Clinical Pharmacy, 48(4), 1412-1423. https://doi.org/10.1007/s11096-026-02119-x

Vancouver

Liu C, Lyu L, Zhang Y, Tian Y, Yuan J, Li C, et al. Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures. International Journal of Clinical Pharmacy. 2026;48(4):1412-1423. doi:10.1007/s11096-026-02119-x

BibTeX
@article{Liu2026,
  author = {Liu, Chenning and Lyu, Liyang and Zhang, Yufan and Tian, Yingyi and Yuan, Jing and Li, Chihua and Hu, Yuanjia},
  title = {Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures},
  journal = {International Journal of Clinical Pharmacy},
  year = {2026},
  volume = {48},
  number = {4},
  pages = {1412--1423},
  doi = {10.1007/s11096-026-02119-x}
}
Kostenlos starten →